肿瘤浸润B细胞可区分免疫检查点阻断诱导的应答
该探索性转化研究对配对治疗前及治疗早期转移性黑色素瘤活检组织与外周血单个核细胞进行单细胞转录组和表面蛋白组分析,发现B细胞(免疫球蛋白表达及B细胞克隆型丰度)可区分ICB后临床应答,基线肿瘤浸润B细胞克隆型丰度可划分两个不同风险组,并在独立队列中验证。
要点
- 单细胞分析配对治疗前后黑色素瘤活检及外周血,识别与疾病控制或进展相关的细胞群。
- B细胞免疫球蛋白表达及克隆型丰度可区分ICB后临床应答。
- 基线肿瘤浸润B细胞克隆型丰度划分两个风险组,并在独立队列中验证。
核心结论
- 该探索性转化研究为B细胞在ICB治疗期间抗黑色素瘤免疫中的机制作用提供新见解,并支持治疗前B细胞肿瘤浸润作为有前景的预后生物标志物,有待进一步验证作为临床风险分层工具。
研究设计与样本
- 探索性转化研究,对配对治疗前及治疗早期转移性黑色素瘤肿瘤活检和匹配外周血单个核细胞样本进行转录组和表面蛋白组的单细胞分析。
- 比较转移性黑色素瘤患者按治疗前肿瘤浸润B细胞克隆型丰度分组的生存情况。
- 在独立队列中验证基线肿瘤浸润B细胞克隆型丰度划分的两个风险组。
主要发现
- 识别出与疾病控制或进展相关的细胞群,定义可能参与抗肿瘤免疫唤醒的生物学通路的差异表达,并检查治疗期间肿瘤细胞亚群间细胞间通讯模式的变化。
- 发现B细胞(免疫球蛋白表达和B细胞克隆型丰度)可区分ICB后的临床应答,并提出B细胞可能通过主要组织相容性复合体分子递呈抗原而参与抗肿瘤免疫。
- 证明基线肿瘤浸润B细胞克隆型丰度可识别两个不同的风险组,并在独立队列中证实该发现。
局限性
- 该研究为探索性转化研究,原文结论称所支持的预后生物标志物有待进一步验证作为临床风险分层工具。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Immune cell-driven anti-cancer activity is paramount for effective responses to checkpoint inhibitors (ICB). However, the contribution of the different immune cell subsets in the circulation and within the tumour is poorly understood. MATERIALS AND METHODS: To elucidate the role of the different cell subsets in anti-tumour responses elicited by ICB, we performed single-cell analysis of the transcriptome and surface proteome of paired pre- and early on-treatment metastatic melanoma tumour biopsies and matched peripheral blood mononuclear cell samples. We next compared the survival of metastatic melanoma patients treated with ICB according to the abundance of pre-treatment tumour-infiltrating B cell clonotypes. RESULTS: We identified cell clusters associated with disease control or progression, defined differential expression of biological pathways likely involved in the immune awakening against the tumour and examined how cell-cell communication patterns between the tumour cell subsets change during treatment. Furthermore, we discovered that B cells (immunoglobulin expression and abundance of B cell clonotypes) discriminate the clinical response after ICB and propose that B cells likely contribute to anti-tumour immunity by antigen presentation through major histocompatibility complex molecules. Finally, we demonstrated that the abundance of tumour-infiltrating B cell clonotypes at baseline identifies two distinct risk groups, a finding that we confirmed in an independent cohort. CONCLUSIONS: Our exploratory translational study provides new insights on the mechanistic role of B cells in anti-melanoma immunity during treatment with ICB. Additionally, we support pre-treatment B cell tumour infiltration as a promising prognostic biomarker to be further validated as a tool for clinical risk stratification.
引用
- Valpione S, Campana LG, Weightman J, et al. Tumour infiltrating B cells discriminate checkpoint blockade-induced responses. Eur J Cancer. 2022. PMID: 36347135. doi:10.1016/j.ejca.2022.09.022
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。